OR WAIT 15 SECS
Sciex Diagnostics, the in vitro diagnostics (IVD) division of Sciex, has announced a joint venture with Zhejiang Dian Diagnostics (Dian).
Sciex Diagnostics, the in vitro diagnostics (IVD) division of Sciex, has announced a joint venture with Zhejiang Dian Diagnostics (Dian). A supplier of medical and diagnostic products and services in China, Zhejiang Dian Diagnostics will partner with Sciex in establishing a site in Hangzhou, China, to develop, register, manufacture, and commercialize Class I, II, and III in vitro diagnostic reagents for Sciex’s liquid chromatography tandem mass spectrometry (LC–MS/MS) system, which was approved by the China Food and Drug Administration (CFDA) earlier this year.
The venture intends to address the lack of readily available IVD assays for Chinese hospital laboratories, a situation that continues to hinder the progress of clinical laboratories across the country. The combination of Sciex’s chromatography and assay resources with Dian’s laboratory network, cold chain logistics, and China-IVD manufacturing experience is expected to quickly address these issues and accelerate China’s clinical laboratory programme.
“Modern-day China contends with many lifestyle factors that can lead to illness. Our aim is to provide wellness testing resources that can help hospitals identify potential health risks before they become chronic,” said Inese Lowenstein, President of Sciex.
“Dian has established many product channels with its wide coverage of high-end medical resources, and this venture will further enrich their existing in vitro diagnostic product lines to enable hospital labs to expand their testing capabilities, and perform tests that they previously were not able to,” said Lowenstein.
“It is an important decision and major breakthrough for Dian to collaborate with Sciex,” said Hai bin Chen, Chairman of Zhenjang Dian Diagnostics. “This joint venture is the first of its kind in China, and by also working closely with CFDA and Health and Family Planning Commission, we believe it will have a profound influence on the future of wellness and diagnostic testing in China,” continued Chen.
A ceremony to celebrate the venture took place at Zhejiang Dian Diagnostics headquarters in Hangzhou, China, attended by Sciex Senior Leadership Executives.
For more information please visit: www.sciex.com